TrialTargeted oncology2025

Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study.

Antoine Desilets et al.PubMed ↗Publisher ↗

No numbers read from the abstract.